At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
letetresgene autoleucel (GSK3377794) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
In Brief
A Phase 2 clinical trial evaluating letetresgene autoleucel (GSK3377794), Cyclophosphamide, and 1 other intervention for Neoplasms. Completed, enrolled 23 participants across 6 sites.
Detailed Summary
This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedDec 2016
Primary CompletionNov 2021
Study CompletionMar 2022
TodayJul 2026
First PostedDec 14, 2016
Enrollment StartDec 6, 2016
Primary CompletionNov 1, 2021
Study CompletionMar 22, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.5 years ago
Interventions
letetresgene autoleucel (GSK3377794)drug
Letetresgene autoleucel (GSK3377794) as an IV infusion.
Cyclophosphamidedrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Fludarabinedrug
Fludarabine will be used as a lymphodepleting chemotherapy.